STING1 and cancer: These experiments also aim to compare Ara-C/DS to STING agonists to confirm the potential benefits of exploiting the DDR for STING activation, as the data presented herein suggests that Ara-C has a greater impact on the upregulation of immune ligands on cancer cells as compared to cGAMP.